|
News For MDT;BSX;STJ From The Last 14 Days Check below for free stories on MDT;BSX;STJ the last two weeks. |
|
|
| May 16, 2013 |
| 16:13 EDT |  | BSX | Vascular Solutions files patent infringement complaint against Boston Scientific
Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. |
|
| 13:32 EDT |  | MDT | Medtronic volatility flat into Q4 and outlook
 Subscribe for More Information |
|
| 10:03 EDT |  | MDT | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 08:05 EDT | | STJ | St. Jude Medical's 3-D vessel reconstruction system approved in Europe
St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform. |
|
| 07:51 EDT |  | BSX | Boston Scientific price target raised to $12 from $9 at JMP Securities
JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. |
|
| 07:28 EDT |  | BSX | I/O Central to host a conference
Subscribe for More Information |
|
| 06:32 EDT | | MDT | Medtronic downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information |
|
| May 14, 2013 |
| 15:33 EDT | | BSX | Boston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. |
|
| 08:09 EDT | | STJ | St. Jude Medical announces first patient enrolled in EnligHTN III study
Subscribe for More Information |
|
| May 10, 2013 |
| 15:49 EDT | | MDT | Medtronic defibrillators demonstrate success of shock avoidance
Subscribe for More Information |
| |
| 10:00 EDT |  | BSX | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:03 EDT | | BSX | Boston Scientific receives CEO Mark approval for Rhythmia mapping system
Subscribe for More Information |
|
| 05:46 EDT | | BSX | Boston Scientific upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information |
|
| May 9, 2013 |
| 14:01 EDT | | STJ | St. Jude says analysis demonstrates safety, reliability of Optim-insulated leads
Subscribe for More Information |
|
| 12:04 EDT | | BSX | Boston Scientific says data show Watchman device superior to warfarin
Boston Scientific reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN Left Atrial Appendage Closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolization. The data demonstrated significant reductions in both cardiovascular and all death compared to warfarin. The data were presented today as a late-breaking clinical trial at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions. |
|
| 09:27 EDT | | BSX, STJ | Leerink's medical devices analyst holds a conference call
Subscribe for More Information |
|
| May 8, 2013 |
| 08:09 EDT | | STJ | St. Jude Medical announces CE Mark approval of ICDs, CRT-Ds
Subscribe for More Information |
|
| 07:38 EDT | | BSX, MDT | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information |
|
| May 6, 2013 |
| 09:19 EDT | | MDT | Medtronic receives FDA approval for newest cardiac devices
Medtronic announced FDA approval and U.S. launch of its newest cardiac devices: the Viva portfolio of cardiac resynchronization therapy with defibrillation, or CRT-D, devices, and the Evera portfolio of implantable cardioverter-defibrillators. |
|
| 08:06 EDT | | BSX | Boston Scientific completes first-in-human clinical trial of IntellaTip Mifi XP
Boston Scientific completed a first-in-human clinical trial utilizing the IntellaTip MiFi XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia originating in the right atrium of the heart that affects nearly one million people in the United States. This single center feasibility trial enrolled 10 patients and was led by Prash Sanders, MBBS, PhD, FHRS, director of the Centre for Heart Rhythm Disorders at the University of Adelaide and the Royal Adelaide Hospital. Patients with type 1 atrial flutter may exhibit symptoms that include palpitations, shortness of breath, fatigue, lightheadedness and fainting. Catheter ablation, a procedure in which localized electrical energy is delivered into the heart tissue aimed at restoring the continuous normal rhythm, has become a first-line treatment approach for patients with recurrent type 1 atrial flutter and demonstrates more successful short- and long-term outcomes compared to anti-arrhythmic drug therapy. |
| |
|
|
|
|
